Solid Biosciences shares are trading higher after the company announced multiple presentations at the ESGCT Annual Congress showcasing its SGT-003 gene therapy program and proprietary POLARIS-101 capsid platform.

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial

The European Commission has granted Orphan designation to Solid Biosciences' SGT-212 for the treatment of Friedreich's ataxia, while the company reports continued progress in its Phase 1b FALCON clinical trial.

UBS Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $20

This Brinker Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Analysts initiated coverage: Neutral on MCD; Buy on MOVE and EAT; Outperform on SLDB; Equal-Weight on GOLF, with price targets announced.